Claims for Patent: 8,222,202

Summary for Patent: 8,222,202

Title:	Use of peptidic vasopressin receptor agonists
Abstract:	The present invention relates to the use of novel compounds for the manufacture of a medicament for treatment of, inter alia, conditions associated with critical care sepsis, septic shock, hepatorenal syndrome type I, hypertension induced by endstage venal disease, severe burns, thermal injury as well as to a method for treatment of the conditions by administering the compounds. The compounds used are represented by the general formula (1), as further defined in the specification. ##STR00001##
Inventor(s):	Laporte; Regent (San Diego, CA), Riviere; Pierre J. M. (San Diego, CA)
Assignee:	Ferring B.V. (NL)
Application Number:	12/223,673
Patent Claims:	1. A method of treating a condition selected from: hypertensive gastropathy bleeding; prolonged and severe hypotension; intradialytic hypotension; vasodilatory shock induced by cardio-pulmonary bypass; milrinone-induced vasodilatory shock in congestive heart failure; anaphylactic shock; cardiovascular instability induced by brain death; acute respiratory distress syndrome; acute lung injury; shock induced by metformin intoxication, mitochondrial disease, cyanide poisoning, or by vascular leak syndrome induced by interleukin-2 or another cytokine, denileukin diftitox or another immunotoxin, or ovarian hyperstimulation syndrome; hypertension induced by end-stage renal disease; irritable bowel disease; reperfusion injury; infant respiratory distress syndrome; severe acute respiratory syndrome; ascites; vasodepressor syncope; toxic shock syndrome; and idiopathic systemic capillary leak syndrome (Clarkson's disease); wherein the method comprises administering to an animal patient in need of such treatment a therapeutically effective amount of a compound having the formula (I): ##STR00006## wherein: Ar is an aryl group selected from aromatic carbocyclic ring systems, five- or six-membered heteroaromatic ring systems and bicyclic heteroaromatic ring systems; m is selected from 1, 2 and 3; n is selected from 0, 1, 2, 3 and 4; p is selected from 2, 3 and 4; R.sub.1, R.sub.2 and R.sub.3 are independently selected from H, OH, alkyl, O-alkyl and OC(O)-alkyl; alkyl is selected from C.sub.1-6 straight and C.sub.4-8 branched chain alkyl and optionally has at least one hydroxyl substituent; and when n=0, R.sub.1 and R.sub.2 optionally together form a nitrogen containing ring structure comprising from 2 to 5 carbon atoms; with the proviso that when Ar is phenyl, m=2, n=0, R.sub.1=R.sub.2=H, and p is 3 or 4, R.sub.3 is not H; or a pharmaceutically acceptable salt thereof or a solvate thereof. 2. The method as defined in claim 1 wherein the condition comprises acute respiratory distress syndrome or acute lung injury. 3. The method as defined in claim 1 wherein the condition comprises: shock induced by metformin intoxication, mitochondrial disease, cyanide poisoning, or by vascular leak syndrome induced by interleukin-2 or another cytokine, denileukin diftitox or another immunotoxin, or ovarian hyperstimulation syndrome; hypertension induced by end-stage renal disease; irritable bowel disease; reperfusion injury; infant respiratory distress syndrome; severe acute respiratory syndrome; ascites; vasodepressor syncope; toxic shock syndrome; or idiopathic systemic capillary leak syndrome (Clarkson's disease). 4. The method according to claim 1, wherein Ar is selected from phenyl, 2- or 3-thienyl, 2- or 3-furyl, 2-, 3- or 4-pyridyl and 2-, 4- or 5-thiazolyl. 5. The method according to claim 1, wherein R.sub.1 is H. 6. The method according to claim 1, wherein p is 2 or 3. 7. The method according to claim 1, wherein R.sub.2 is selected from H, OH, CH.sub.3, CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2, CH(CH.sub.2OH).sub.2, CH(OH)CH.sub.3, OCH.sub.3 and OCH.sub.2CH.sub.2OH. 8. The method according to claim 1, wherein R.sub.3 is selected from H, methyl, ethyl, n-propyl, i-propyl and i-amyl. 9. The method according to claim 1, wherein the compound is selected from the group consisting of: ##STR00007## and pharmaceutically acceptable salts thereof. 10. The method of claim 1, wherein the animal patient is a human. 11. The method of claim 1, wherein the condition is anaphylactic shock. 12. The method according to claim 1, wherein the compound is: ##STR00008## or a pharmaceutically acceptable salt thereof. 13. The method according to claim 1, wherein the compound is: ##STR00009## or a pharmaceutically acceptable salt thereof. 14. The method according to claim 1, wherein the compound is: ##STR00010## or a pharmaceutically acceptable salt thereof. 15. The method according to claim 1, wherein the compound is: ##STR00011## or a pharmaceutically acceptable salt thereof. 16. The method according to claim 1, wherein the compound is: ##STR00012## or a pharmaceutically acceptable salt thereof. 17. The method according to claim 1, wherein the compound is: ##STR00013## or a pharmaceutically acceptable salt thereof. 18. The method according to claim 1, wherein the compound is: ##STR00014## or a pharmaceutically acceptable salt thereof.

Details for Patent 8,222,202

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eisai, Incorporated	ONTAK	denileukin diftitox	Injection	103767	02/05/1999		2026-02-13